Literature DB >> 15841045

The effect of apoptotic activity, survivin, Ki-67, and P-glycoprotein expression on prognosis in pancreatic carcinoma.

Ozül Sagol1, Tugba Yavuzsen, Ilhan Oztop, Cagnur Ulukus, Ugur Ylmaz, Mehmet Alakavuklar, Sedat Karademir, Funda Obuz, Hüseyin Astarcoğlu, Ibrahim Astarcoglu.   

Abstract

OBJECTIVES: The pathogenetic mechanisms that regulate the aggressive behavior of pancreatic cancer still remain to be clarified. Alterations in the apoptotic pathway and proliferative activity of tumor cells as well as mechanisms contributing to the intrinsic drug resistance of pancreatic tumors have been investigated. Survivin is a recently described antiapoptotic protein, which, when overexpressed, is associated with worse prognosis in a majority of tumors. P-glycoprotein, a product of multidrug resistance gene-1 (MDR-1) was reported to be expressed in drug-resistant tumors. The purpose of this study was to investigate whether apoptosis, its regulation by survivin, tumor cell proliferation, and P-glycoprotein expression have a significant role on the biologic behavior of pancreatic adenocarcinoma.
METHODS: Tumors of 45 patients with pancreatic adenocarcinoma were studied for the detection of survivin, P-glycoprotein, and Ki-67 expression by immunohistochemical method and apoptotic index by TUNEL method. Immunohistochemical staining was scored and Ki-67 and apoptotic indices were expressed as percentage of stained cells.
RESULTS: Immunohistochemistry for survivin and P-glycoprotein revealed positive staining in 7 (15.4%) and 36 (79.5%) of the 45 tumors, respectively. The mean Ki-67 proliferative index was 43.75 +/- 25.30%. The mean apoptotic index evaluated with the TUNEL method was 37.12 +/- 34.55% for the whole group. We found no significant association between apoptotic index, expressions of survivin and P-glycoprotein, and clinicopathologic variables and survival.
CONCLUSIONS: Apoptotic activity, survivin, and P-glycoprotein expression failed to predict the disease extent and biologic behavior in pancreatic adenocarcinoma in our cases.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15841045     DOI: 10.1097/01.mpa.0000160285.87322.3e

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  8 in total

1.  Effect of apoptotic and proliferative indices, P-glycoprotein and survivin expression on prognosis in laryngeal squamous cell carcinoma.

Authors:  Da-Wei Li; Shang Gao; Bin Shen; Pin Dong
Journal:  Med Oncol       Date:  2010-09-23       Impact factor: 3.064

2.  High expression of survivin is prognostic of shorter survival but not predictive of adjuvant gemcitabine benefit in patients with resected pancreatic adenocarcinoma.

Authors:  Hao Xie; Wei Jiang; Shu-Yuan Xiao; Xiuli Liu
Journal:  J Histochem Cytochem       Date:  2012-11-04       Impact factor: 2.479

3.  Pancreatic cancer-specific cell death induced in vivo by cytoplasmic-delivered polyinosine-polycytidylic acid.

Authors:  Praveen Bhoopathi; Bridget A Quinn; Qin Gui; Xue-Ning Shen; Steven R Grossman; Swadesh K Das; Devanand Sarkar; Paul B Fisher; Luni Emdad
Journal:  Cancer Res       Date:  2014-09-09       Impact factor: 12.701

4.  Prognostic value of glucosylceramide synthase and P-glycoprotein expression in oral cavity cancer.

Authors:  Ji Won Kim; Yangsoon Park; Jong-Lyel Roh; Kyung-Ja Cho; Seung-Ho Choi; Soon Yuhl Nam; Sang Yoon Kim
Journal:  Int J Clin Oncol       Date:  2016-03-21       Impact factor: 3.402

Review 5.  Localization and upregulation of survivin in cancer health disparities: a clinical perspective.

Authors:  Salma Khan; Heather Ferguson Bennit; Malyn May Asuncion Valenzuela; David Turay; Carlos J Diaz Osterman; Ron B Moyron; Grace E Esebanmen; Arjun Ashok; Nathan R Wall
Journal:  Biologics       Date:  2015-07-09

6.  Expression and significance of hypoxia-inducible factor-1α and MDR1/P-glycoprotein in laryngeal carcinoma tissue and hypoxic Hep-2 cells.

Authors:  Jin Xie; DA-Wei Li; Xin-Wei Chen; Fei Wang; Pin Dong
Journal:  Oncol Lett       Date:  2013-04-29       Impact factor: 2.967

Review 7.  Can Molecular Biomarkers Change the Paradigm of Pancreatic Cancer Prognosis?

Authors:  Javier Martinez-Useros; Jesus Garcia-Foncillas
Journal:  Biomed Res Int       Date:  2016-09-01       Impact factor: 3.411

8.  An ABCG2 non-substrate anticancer agent FL118 targets drug-resistant cancer stem-like cells and overcomes treatment resistance of human pancreatic cancer.

Authors:  Xiang Ling; Wenjie Wu; Chuandong Fan; Chao Xu; Jianqun Liao; Laurie J Rich; Ruea-Yea Huang; Elizabeth A Repasky; Xinjiang Wang; Fengzhi Li
Journal:  J Exp Clin Cancer Res       Date:  2018-10-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.